Janet E. Murphy

6.2k total citations · 1 hit paper
57 papers, 1.4k citations indexed

About

Janet E. Murphy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Janet E. Murphy has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Janet E. Murphy's work include Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (16 papers) and Colorectal Cancer Treatments and Studies (11 papers). Janet E. Murphy is often cited by papers focused on Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (16 papers) and Colorectal Cancer Treatments and Studies (11 papers). Janet E. Murphy collaborates with scholars based in United States, Switzerland and Canada. Janet E. Murphy's co-authors include David P. Ryan, Lawrence S. Blaszkowsky, Jill N. Allen, Jennifer Y. Wo, Theodore S. Hong, Jeffrey W. Clark, Cristina R. Ferrone, Carlos Fernández‐del Castillo, Keith D. Lillemoe and Eunice L. Kwak and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Janet E. Murphy

57 papers receiving 1.3k citations

Hit Papers

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Ind... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
    2018 362 citations Janet E. Murphy, Jennifer Y. Wo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet E. Murphy United States 16 1.0k 456 455 329 294 57 1.4k
Taek‐Keun Nam South Korea 21 715 0.7× 421 0.9× 657 1.4× 130 0.4× 94 0.3× 101 1.5k
M. Priyanthi Kumarasinghe Australia 22 482 0.5× 398 0.9× 527 1.2× 263 0.8× 114 0.4× 83 1.2k
Lakshmi Rajdev United States 20 599 0.6× 300 0.7× 296 0.7× 98 0.3× 149 0.5× 64 1.1k
Jeanette D. Cheng United States 19 1.1k 1.1× 363 0.8× 993 2.2× 333 1.0× 198 0.7× 27 1.7k
Nobuyuki Ohike Japan 23 1.6k 1.5× 439 1.0× 1.1k 2.4× 690 2.1× 267 0.9× 114 2.1k
Martin Görner Germany 13 585 0.6× 215 0.5× 202 0.4× 234 0.7× 273 0.9× 23 939
Kenji Kashiwabara Japan 19 622 0.6× 192 0.4× 490 1.1× 592 1.8× 161 0.5× 48 1.4k
Stefania Bettelli Italy 20 868 0.9× 361 0.8× 181 0.4× 112 0.3× 409 1.4× 55 1.2k
Rami N. Al‐Rohil United States 14 588 0.6× 269 0.6× 432 0.9× 123 0.4× 189 0.6× 61 1.2k
Jacob R. Izbicki Germany 18 576 0.6× 357 0.8× 394 0.9× 69 0.2× 257 0.9× 47 1.3k

Countries citing papers authored by Janet E. Murphy

Since Specialization
Citations

This map shows the geographic impact of Janet E. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet E. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet E. Murphy more than expected).

Fields of papers citing papers by Janet E. Murphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet E. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet E. Murphy. The network helps show where Janet E. Murphy may publish in the future.

Co-authorship network of co-authors of Janet E. Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Janet E. Murphy. A scholar is included among the top collaborators of Janet E. Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet E. Murphy. Janet E. Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huffman, Brandon M., Atrayee Basu Mallick, Nora Horick, et al.. (2023). Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. JAMA Network Open. 6(1). e2249720–e2249720. 8 indexed citations
2.
Wo, Jennifer Y., John P. Plastaras, James M. Metz, et al.. (2019). Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. International Journal of Radiation Oncology*Biology*Physics. 105(1). 90–95. 21 indexed citations
3.
Smart, Alicia, Lipika Goyal, Nora Horick, et al.. (2019). Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology. 27(4). 1122–1129. 27 indexed citations
4.
Murphy, Janet E., Jennifer Y. Wo, David P. Ryan, et al.. (2018). Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology. 36(15_suppl). 4116–4116. 9 indexed citations
5.
McDuff, Susan G. R., Aparna R. Parikh, Mehlika Hazar-Rethinam, et al.. (2018). Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology. 36(4_suppl). 272–272. 7 indexed citations
6.
Rose, Brent S., Devarati Mitra, Theodore S. Hong, et al.. (2017). Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Practical Radiation Oncology. 7(5). e291–e297. 10 indexed citations
7.
Dinaux, Anne M., Ramzi Amri, Liliana Bordeianou, et al.. (2017). The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer—a Large Single-Center Experience. Journal of Gastrointestinal Surgery. 21(7). 1153–1158. 19 indexed citations
8.
Parikh, Aparna, Lipika Goyal, Mehlika Hazar-Rethinam, et al.. (2017). Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Annals of Oncology. 28. iii137–iii137. 5 indexed citations
9.
Mitra, Devarati, Theodore S. Hong, Nora Horick, et al.. (2017). Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Advances in Radiation Oncology. 2(2). 110–117. 39 indexed citations
10.
Elmi, Azadeh, Janet E. Murphy, Sandeep Hedgire, et al.. (2017). Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis. Abdominal Radiology. 42(8). 2101–2107. 12 indexed citations
11.
Miller, Cynthia L., Martin S. Taylor, Motaz Qadan, et al.. (2017). Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery. 21(11). 1831–1840. 14 indexed citations
12.
13.
Ryan, David P., Janet E. Murphy, Devalingam Mahalingam, et al.. (2016). PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals of Oncology. 27. ii108–ii108. 6 indexed citations
14.
Ryan, David P., Janet E. Murphy, Devalingam Mahalingam, et al.. (2016). Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).. Journal of Clinical Oncology. 34(15_suppl). e15525–e15525. 3 indexed citations
15.
Rose, Brent S., Kyung‐Wook Jee, Andrzej Niemierko, et al.. (2015). Irradiation of FDG-PET–Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. International Journal of Radiation Oncology*Biology*Physics. 94(4). 747–754. 26 indexed citations
16.
Bendell, Johanna C., John D. Powderly, Christopher H. Lieu, et al.. (2015). Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 704–704. 86 indexed citations
17.
Weber, Georg F., Robert Rosenberg, Janet E. Murphy, Christian Meyer zum Büschenfelde, & Helmut Friess. (2012). Multimodal treatment strategies for locally advanced rectal cancer. Expert Review of Anticancer Therapy. 12(4). 481–494. 10 indexed citations
18.
Marsh, Antoinette E., Stephen M. Reed, J. P. Dubey, et al.. (2007). Early Migration of Sarcocystis neurona in Ponies Fed Sporocysts. Journal of Parasitology. 93(5). 1222–1225. 8 indexed citations
19.
Silverberg, Mark S., Lucia Mirea, Shelley B. Bull, et al.. (2003). A Population- and Family-Based Study of Canadian Families Reveals Association of HLA DRB1*0103 With Colonic Involvement in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 9(1). 1–9. 76 indexed citations
20.
Silverberg, Mark S., Catherine L. Clelland, Janet E. Murphy, et al.. (2001). Carrier rate of APC I1307K is not increased in inflammatory bowel disease patients of Ashkenazi Jewish origin. Human Genetics. 108(3). 205–210. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taek‐Keun Nam Breakdown of academic impact, for papers by M. Priyanthi Kumarasinghe Breakdown of academic impact, for papers by Lakshmi Rajdev Breakdown of academic impact, for papers by Jeanette D. Cheng Breakdown of academic impact, for papers by Nobuyuki Ohike Breakdown of academic impact, for papers by Martin Görner Breakdown of academic impact, for papers by Kenji Kashiwabara Breakdown of academic impact, for papers by Stefania Bettelli Breakdown of academic impact, for papers by Rami N. Al‐Rohil Breakdown of academic impact, for papers by Jacob R. Izbicki
Rankless by CCL
2026